Carboplatin
Carboplatin (carboplatin) is a small molecule pharmaceutical. Carboplatin was first approved as Paraplatin on 1989-03-03. It is used to treat bone marrow diseases, breast neoplasms, central nervous system neoplasms, endometrial neoplasms, and esophageal neoplasms amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Carboplatin (discontinued: Carboplatin, Paraplatin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carboplatin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PARAPLATIN | CordenPharma | N-019880 DISCN | 1989-03-03 | 3 products, RLD |
| PARAPLATIN | CordenPharma | N-020452 DISCN | 2003-07-14 | 4 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| carboplatin | ANDA | 2026-07-21 |
| kyxata | New Drug Application | 2025-09-02 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9045 | Injection, carboplatin, 50 mg |
Clinical
Clinical Trials
4354 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 278 | 738 | 337 | 13 | 67 | 1288 |
| Lung neoplasms | D008175 | — | C34.90 | 145 | 428 | 134 | 13 | 51 | 697 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 153 | 267 | 103 | 3 | 31 | 488 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 82 | 277 | 80 | 9 | 37 | 442 |
| Neoplasms | D009369 | — | C80 | 278 | 164 | 30 | 4 | 15 | 417 |
| Small cell lung carcinoma | D055752 | — | — | 57 | 169 | 53 | 5 | 19 | 269 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 75 | 124 | 59 | 3 | 16 | 243 |
| Triple negative breast neoplasms | D064726 | — | — | 40 | 148 | 45 | 1 | 11 | 222 |
| Carcinoma | D002277 | — | C80.0 | 48 | 130 | 40 | 1 | 14 | 211 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 43 | 124 | 28 | 1 | 8 | 184 |
Show 26 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fallopian tube neoplasms | D005185 | — | — | 70 | 95 | 49 | — | 7 | 193 |
| Uterine cervical neoplasms | D002583 | — | — | 24 | 59 | 37 | — | 16 | 120 |
| Head and neck neoplasms | D006258 | — | — | 31 | 80 | 15 | — | 4 | 114 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 15 | 71 | 13 | — | 10 | 97 |
| Lymphoma | D008223 | — | C85.9 | 33 | 58 | 8 | — | 5 | 88 |
| Peritoneal neoplasms | D010534 | — | — | 21 | 30 | 16 | — | 3 | 63 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 14 | 27 | 20 | — | 4 | 61 |
| Central nervous system neoplasms | D016543 | — | — | 21 | 32 | 7 | — | 6 | 57 |
| Transitional cell carcinoma | D002295 | — | — | 18 | 31 | 14 | — | 1 | 56 |
| Urinary bladder neoplasms | D001749 | — | C67 | 14 | 33 | 13 | — | 1 | 54 |
Show 148 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 20 | 12 | — | — | 1 | 29 |
| Male breast neoplasms | D018567 | — | — | 6 | 9 | — | — | 4 | 19 |
| Immunotherapy | D007167 | — | — | 1 | 15 | — | — | 3 | 18 |
| Pancreatic ductal carcinoma | D021441 | — | — | 13 | 6 | — | — | — | 15 |
| Cystadenocarcinoma | D003536 | — | — | 7 | 5 | — | — | 1 | 13 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 7 | 4 | — | — | 1 | 11 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 8 | 5 | — | — | 1 | 10 |
| T-cell lymphoma peripheral | D016411 | — | — | 5 | 6 | — | — | 1 | 10 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 6 | 4 | — | — | 1 | 9 |
| T-cell lymphoma | D016399 | — | — | 4 | 6 | — | — | 1 | 9 |
Show 196 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | 3 | — | — | — | — | 3 |
| Myeloid leukemia accelerated phase | D015465 | — | — | 3 | — | — | — | — | 3 |
| Blast crisis | D001752 | — | — | 3 | — | — | — | — | 3 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | — | — | — | — | 2 |
| Myeloid leukemia chronic-phase | D015466 | — | — | 2 | — | — | — | — | 2 |
| Thrombocytosis | D013922 | — | D75.83 | 2 | — | — | — | — | 2 |
| Communicable diseases | D003141 | — | — | 2 | — | — | — | — | 2 |
| Camurati-engelmann syndrome | D003966 | Orphanet_1328 | Q78.3 | 1 | — | — | — | — | 1 |
| And serous mucinous cystic neoplasms | D018297 | — | — | 1 | — | — | — | — | 1 |
| Enteropathy-associated t-cell lymphoma | D058527 | — | C86.2 | 1 | — | — | — | — | 1 |
Show 33 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | — | — | — | 3 | 3 |
| Taste disorders | D013651 | — | — | — | — | — | — | 2 | 2 |
| Dysgeusia | D004408 | — | R43.2 | — | — | — | — | 2 | 2 |
| Carcinogenesis | D063646 | — | — | — | — | — | — | 1 | 1 |
| Methylation | D008745 | — | — | — | — | — | — | 1 | 1 |
| Hypoxia | D000860 | — | R09.02 | — | — | — | — | 1 | 1 |
| Immunoglobulin light-chain amyloidosis | D000075363 | — | — | — | — | — | — | 1 | 1 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | — | — | — | — | 1 | 1 |
| Ageusia | D000370 | EFO_1001758 | — | — | — | — | — | 1 | 1 |
| Breast diseases | D001941 | — | N60-N65 | — | — | — | — | 1 | 1 |
Show 27 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Carboplatin |
| INN | carboplatin |
| Description | Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
|
| Classification | Small molecule |
| Drug class | antineoplastics (platinum derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 41575-94-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1351 |
| ChEBI ID | 31355 |
| PubChem CID | 10339178 |
| DrugBank | DB00958 |
| UNII ID | BG3F62OND5 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Carboplatin, Kyxata
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
117,325 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use